Andrew Blauvelt
Chairman of Scientific Advisory BoardDr. Andrew Blauvelt had been Member of Advisory Board of Lipidio Pharmaceuticals Inc. since May 2023 until 2025. Dr. Blauvelt is an Investigator (and former President) at the Oregon Medical Research Center (OMRC), a site dedicated to performing high quality clinical research studies in dermatology. Previously, he held senior staff positions at the NIH (Senior Investigator), Oregon Health & Science University (Professor) and the Portland VA Medical Center (Chief). Dr. Blauvelt is Chairman of Scientific Advisory Board at Oruka Therapeutics, Inc. Dr. Blauvelt is a renowned expert in Langerhans cell biology, T cell immunology, virology, psoriasis and atopic dermatitis. He has published over 350 papers and spoken across the world on these topics. In recent years, he has been the international lead/senior investigator on a number of important clinical trials, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, BE ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, POETYK PSO-1, CHRONOS, ECZTEND, JADE REGIMEN, HEADS UP, ADhere and STRATUM. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, the International Eczema Council and the Scientific Advisory Committee of the National Psoriasis Foundation. In 2021 and 2022, he made the lists of Highly Cited Researchers, representing the top 1% of cited scientists in the world. He received his medical degree at Michigan State University and a healthcare MBA at Oregon Health & Science University. Dr Blauvelt received his undergraduate degree in electrical engineering at Purdue University.
Positions
- Company NameOruka Therapeutics, Inc.Stock CodeORKAPositionChairman of Scientific Advisory BoardColleagues
- LOLawrence Otto KleinPresident, CEO & Director
- SKSamarth KulkarniIndependent Chairman of Board
- PTPaul T. QuinlanGeneral Counsel & Secretary
- JGJoana GoncalvesChief Medical Officer
- AAArjun AgarwalSenior VP of Finance & Treasurer
- LSLaura SandlerChief Operating Officer
- KMKristine M. BallIndependent Director
- PEPeter Evan HarwinIndependent Director
